Skip to main content
C
CorpDigest
Search

AbbVie Inc.

BiopharmaceuticalFounded 2013
Reviewed by Swet Parvadiya
Company data updated: September 2026
Independent Editorial Analysis
12 historical events · Editorial analysis

AbbVie Company Profile: Revenue, Business Model & Strategy

Research depth: 12 milestones · 9 FAQs

AbbVie is a global biopharmaceutical company created from Abbott Laboratories in 2013. It reported $61.160 billion in FY2025 net revenue and is led by chairman and CEO Robert A. Michael.

How AbbVie makes money: AbbVie earns revenue from global sales of prescription medicines and Allergan Aesthetics products. Its FY2025 portfolios were led by immunology at $30.406 billion, neuroscience at $10.767 billion, oncology at $6.655…

Revenue & employeesCEO historyFoundersHistory
Annual Revenue (FY2025)$61.2B
Employees57,000
CEORobert A. Michael
Founded2013
IndustryPharmaceuticals
By Swet ParvadiyaLast reviewed:
Data sources: annual reports, SEC filings, methodology
Industry:Biopharmaceutical

AbbVie Inc. key figures

AbbVie Inc. had revenue of $61.2B for fiscal year 2025, up 8.6% from FY2024. Net income was $4.2B, a net margin of 6.9%.

Source: SEC EDGAR company facts for AbbVie Inc. · Last reviewed September 2026

Revenue growth, FY2016 to FY2025
+10.1% a year
Compound annual rate, $25.6B to $61.2B
Peak revenue year
FY2025
The latest annual year is the highest in this series
Revenue per employee
$1.1M
FY2025 revenue divided by 57,000 employees; headcount may use another date
Current chief executive
Robert A. Michael
In the role since 2024 (2 years)
Documented transactions
4
Between 2015 and 2024
Founded
2013
13 years ago
Where was AbbVie founded?
AbbVie was founded in Delaware, United States in 2013. wikidata.org
When did AbbVie start?
AbbVie was founded in 2013.
How old is AbbVie?
AbbVie is 13 years old as of 2026.
In-Depth Analysis
283 words · 2 min read

AbbVie Inc. is a North Chicago biopharmaceutical company formed through Abbott Laboratories' 2013 separation of its research-based pharmaceutical business. AbbVie reported $61.160 billion in FY2025 net revenue and is led by chairman and CEO Robert A. Michael.

What Does AbbVie Do?

AbbVie develops, manufactures, and sells prescription medicines in immunology, neuroscience, oncology, eye care, and other therapeutic areas, as well as Allergan Aesthetics products. Its major products include Skyrizi, Rinvoq, Humira, Botox, Vraylar, Imbruvica, Venclexta, Elahere, Ubrelvy, and Qulipta.

How Does AbbVie Make Money?

AbbVie earns revenue from medicine and aesthetics-product sales. In FY2025, immunology generated $30.406 billion, neuroscience $10.767 billion, oncology $6.655 billion, and aesthetics $4.860 billion.

How Was AbbVie Formed?

AbbVie launched as an independent public company in January 2013 after Abbott Laboratories separated its research-based pharmaceutical business. It therefore has a corporate spin-off origin rather than conventional individual founders. Richard A. Gonzalez was chairman and CEO at launch and served as CEO through June 2024.

What Changed After Humira Lost U.S. Exclusivity?

U.S. biosimilar competition reduced Humira revenue, while Skyrizi and Rinvoq grew. In FY2025 those two products generated $25.866 billion combined, compared with $4.540 billion for Humira.

Which Companies Has AbbVie Acquired?

Major acquisitions include Pharmacyclics in 2015, Allergan in 2020, and ImmunoGen and Cerevel Therapeutics in 2024. These transactions added oncology, neuroscience, eye care, and aesthetics assets.

Who Leads AbbVie?

Robert A. Michael became CEO on July 1, 2024 and chairman on July 1, 2025. He succeeded Richard A. Gonzalez, who had served as CEO since AbbVie's formation.

What Are AbbVie's Main Risks?

AbbVie's Form 10-K identifies risks including loss of intellectual-property protection, competition, clinical-development setbacks, product safety issues, litigation, government action, and changes in pricing and reimbursement.

Table of Contents

AbbVie Inc. Key Facts

CompanyAbbVie Inc.
Annual revenue change+8.6% (FY2024–FY2025)
Financials$61.2B (FY2025, last reviewed September 2026)
Market Cap$465.8B
FY2025 net income$4.2B
Last reviewedBy Swet Parvadiya, Founder & Editor - September 2026
Founded2013
Founder(s)Abbott Laboratories (spin-off origin)
CEORobert A. Michael
HeadquartersNorth Chicago, Illinois
IndustryBiopharmaceutical
Employees57,000+

AbbVie Company Profile: Revenue, Business Model & Strategy

"Humira once accounted for a large share of AbbVie's revenue. By FY2025, Skyrizi and Rinvoq together generated $25.866 billion, while Humira revenue had declined to $4.540 billion after U.S. biosimilar entry."

AbbVie is a global biopharmaceutical company created from Abbott Laboratories in 2013. It reported $61.160 billion in FY2025 net revenue and is led by chairman and CEO Robert A. Michael.

Revenue

$61.2B

Founded

2013

Author: CorpDigest Research DeskCompany Research

Recorded annual revenue change

AbbVie Inc. had $56.3B of annual revenue in FY2024 and $61.2B in FY2025. Revenue rose 8.6% between those fiscal years.

Source for FY2025

Compare AbbVie Inc. With

AbbVie Inc. vs AmgenStrategic Comparison
AbbVie Inc. vs Eli LillyStrategic Comparison
AbbVie Inc. vs Johnson And JohnsonStrategic Comparison

Explore AbbVie In Depth

Detailed research across every dimension of AbbVie — history, financials, leadership, and strategy.

Company History

AbbVie became an independent public biopharmaceutical company in January 2013 after Abbott Laboratories separated its research-based pharmaceutical business. Humira initially dominated its portfolio.

Full AbbVie history →

Revenue & Financials

AbbVie had $61.2B in revenue for fiscal year 2025. Data covers 10 fiscal years. Market capitalization stands at approximately $466B.

AbbVie financials →

Founders

AbbVie was founded by Abbott Laboratories (spin-off origin) in 2013 in Delaware, United States. Explore each founder's background, motivations, and their role in building the company.

AbbVie founders →

CEO & Leadership

AbbVie is currently led by Robert A. Michael. Explore the full CEO history — leadership transitions, tenures, and the strategic decisions of each chief executive.

AbbVie CEO history →

Acquisitions

AbbVie has completed 4 documented acquisitions. Explore the full acquisition history and strategic rationale behind each deal.

AbbVie acquisitions →

Competitive Strategy

AbbVie is expanding approved uses and commercial reach for Skyrizi and Rinvoq while investing in oncology and neuroscience.

AbbVie strategy →

Related Company Comparisons

CorpDigest Research Desk

 Research Profile

Our analysts compile business strategy profiles from public financial filings, press releases, and analyst reports. Each profile is reviewed for accuracy before publication by our editorial desk and updated on a rolling basis.

About the Author →Our Methodology →

Sources & References

All data point citations [1], [2], etc. in the tables above refer to these primary sources.

Financial data on this page is sourced from SEC EDGAR filings, official earnings releases, and verified press statements. Revenue figures are reviewed and updated periodically. Read our full data methodology ->

Editorial Methodology

Company Research

We use company filings, annual reports, company statements and press reports, with primary sources preferred where available. Each financial row shows its recorded source. Full-year figures are separated from annualized run-rates, partial periods and forecasts; unaudited figures carry a label. Source detail varies by company, so check the linked material when the reporting basis matters.

1. Primary Sources

Public companies may provide filings and annual reports. Private-company figures may come from statements or press coverage. A missing figure stays missing, and a source link should identify where its number came from.

2. Expert Curation

We organize company records and review claims for strategic context, source quality and clarity. Pages show a review date where one is recorded.

3. Multi-Pass Audit

Technical checks flag inconsistent figures and missing links. Editorial review of the underlying source remains necessary for claims those checks cannot verify.

Swet Parvadiya
SEC filings & public records methodology
Sourced from public financial records

Frequently Asked Questions About AbbVie

What is AbbVie and what does it do?

AbbVie is a publicly traded biopharmaceutical company formed in 2013 after separation from Abbott Laboratories. It develops and sells medicines in immunology, neuroscience, oncology, eye care, and other areas, plus Allergan Aesthetics products.

What was AbbVie's FY2025 revenue?

AbbVie reported FY2025 net revenue of $61.160 billion and net income of $4.226 billion.

Who founded AbbVie?

AbbVie was not founded as a conventional startup. It was formed through Abbott Laboratories' separation of its research-based pharmaceutical business in 2013. Richard A. Gonzalez was chairman and CEO at launch and is described by AbbVie as its founding CEO.

Who is AbbVie's CEO?

Robert A. Michael became chief executive officer on July 1, 2024 and chairman on July 1, 2025.

What are AbbVie's largest current products?

In FY2025, Skyrizi generated $17.562 billion and Rinvoq generated $8.304 billion. Other major products included Humira, Botox Therapeutic, Botox Cosmetic, Vraylar, Imbruvica, and Venclexta.

How did AbbVie acquire Botox?

AbbVie acquired Allergan in May 2020. The transaction added Botox Therapeutic, Botox Cosmetic, Juvederm, Vraylar, Ubrelvy, and other assets.

What is AbbVie's stock ticker?

AbbVie trades on the New York Stock Exchange under ticker ABBV.

Who owns AbbVie?

AbbVie is an independent, publicly traded biopharmaceutical company that was spun off from Abbott Laboratories in 2013.

Does AbbVie own Botox?

Yes, AbbVie acquired Allergan, the maker of Botox, in a $63 billion deal completed in 2020.

Strategic Face-Off

Head-to-Head Comparisons

How does AbbVie Inc. stack up against its biggest rivals? Compare revenue, business models, SWOT, and competitive moats side by side.

RivalryVS

AbbVie Inc. vs Johnson & Johnson

Revenue scale, margin comparison, and long-term moat analysis.

Compare Analysis
RivalryVS

AbbVie Inc. vs Eli Lilly and Company

Revenue scale, margin comparison, and long-term moat analysis.

Compare Analysis
RivalryVS

AbbVie Inc. vs Amgen Inc.

Revenue scale, margin comparison, and long-term moat analysis.

Compare Analysis

Related Competitor Intelligence

Compare market positioning with top industry peers

Competitor

Johnson & Johnson

View Competitor Intelligence
Competitor

Eli Lilly and Company

View Competitor Intelligence
Competitor

Pfizer Inc.

View Competitor Intelligence
Competitor

Merck & Co., Inc.

View Competitor Intelligence
Competitor

Amgen Inc.

View Competitor Intelligence
Competitor

Bristol-Myers Squibb Company

View Competitor Intelligence

Explore Related Pages for AbbVie Inc.

History & FailuresTimeline, setbacks, and key milestonesFinancialsRevenue history and fiscal metricsCompetitive StrategyRivals, benchmarks, and SWOT analysis

Related Competitor Intelligence

Compare market positioning with top industry peers

Competitor

Johnson And Johnson

View Competitor Intelligence
Competitor

Eli Lilly

View Competitor Intelligence
Competitor

Pfizer

View Competitor Intelligence
Competitor

Merck

View Competitor Intelligence
Competitor

Amgen

View Competitor Intelligence
Competitor

Bristol Myers Squibb

View Competitor Intelligence

Explore AbbVie

Core profile pages, founders and related research hubs for this company.

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.